Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lemborexant - Eisai

Next Previous
Drug Profile

Lemborexant - Eisai

Alternative Names: DAYVIGO; DAYVIGOTM; E-2006; LEM - Eisai

Latest Information Update: 27 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eisai Inc
  • Class Amides; Cyclopropanes; Fluorobenzenes; Pyridines; Pyrimidines; Sleep disorder therapies; Small molecules
  • Mechanism of Action Orexin receptor type 1 antagonists; Orexin receptor type 2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Insomnia
  • Phase II Circadian rhythm sleep disorders
  • No development reported Chronic obstructive pulmonary disease; Sleep apnoea syndrome

Most Recent Events

  • 28 May 2025 Eisai plans to launch Lemborexant in China by June 2025
  • 27 May 2025 Registered for Insomnia in China (PO) (Eisai pipeline, August 2025)
  • 24 May 2024 Eisai completes a phase II trial for Insomnia in South Korea (PO, Tablet) (NCT05594589)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top